Dr. Byung Ha Lee is the Chief Business Officer at Huonslab Co., Ltd., S. Korea, where he leverages his extensive 15+ years of experience in biopharmaceutical R&D to drive strategic growth and commercialization initiatives. A highly accomplished scientific executive, Dr. Lee's expertise spans the full drug development lifecycle, with a primary focus on oncology, rare diseases, and immunology. Previously, as Chief Scientific Officer at NeoImmuneTech, Inc., he provided executive leadership for the entire R&D engine, ensuring the integration of translational research into clinical development plans. Dr. Lee is highly skilled in establishing and managing strategic collaborations with major pharmaceutical companies, KOLs, and academic institutions, a capability honed through his previous roles at Genexine and Samsung Biomedical Research Institute, where he also led successful business development initiatives. Dr. Lee holds a Ph.D. in Biomedical Sciences-immunology from the University of Florida, complemented by postdoctoral training at the NIH, USA. He is a data-driven leader with a proven track record of converting scientific innovation into commercial opportunities and building value through strategic alliances. Dr. Lee is a data-driven, results-oriented leader adept at navigating complex challenges, managing resources effectively, and translating innovative science into meaningful therapeutic advancements and strategic business opportunities for Huonslab.